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Abstract 
Described are studies focused on prodrug delivery of a doxorubicin-formaldehyde 
conjugate, doxazolidine (Doxaz). Designed for targeted activation by the serine protease 
plasmin, Protease-Activated Doxazolidine (PAD) embodies a new approach to selective cancer 
treatment. Following a model developed by the Koch laboratory, the PAD prodrug consists of a 
peptide tag attached to Doxaz via a self-eliminating spacer. Enzymatic cleavage of the peptide 
and subsequent spacer elimination results in release of active Doxaz into the tumor environment 
from the otherwise inactive prodrug. Problems in the current synthesis of PAD are addressed in 
steps taken towards a new synthetic pathway. Additionally, this study addresses preliminary 
biological evaluation of PAD activation and treatment feasibility through multiple enzyme and 
cancer cell assays. Finally, this work addresses the specific role of the plasmin system in PAD 
activation through RNA interference. Using short hairpin RNA to knockdown key components 
of the plasmin activation pathway, a more accurate portrayal of the plasmin system’s role in 
PAD activation can be attained. Results suggest PAD is a feasible drug candidate and offer 
encouragement for advanced evaluation as a novel therapeutic. 
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Introduction 
Since the 1970s, the anthracycline doxorubicin (Dox, Adriamycin; Figure 1) has been a 
mainstay in cancer treatment. First isolated from the soil microbe Streptomyces peucetius, Dox 
exhibits significant antitumor activity against a variety of cancer types.1-3 As with many cancer 
therapeutics, Dox treatment is hampered by adverse side effects, the most notable of which is 
irreversible cardiotoxicity.4 In addition, acquired tumor resistance further limits clinical success.4 
Because of these problems, much research has been conducted to elucidate the cytotoxic 
mechanisms of Dox-caused death to cancer cells and healthy heart cells. The exact mechanisms 
still remain unclear; however, the anticancer mechanism of Dox is known to be topoisomerase II 
(TOP2) dependent, whereas Dox cardiotoxicity is thought to stem from induction of reactive 
oxygen species.5  
Discovered by the Koch laboratory, doxazolidine (Doxaz), is a formaldehyde conjugate 
of Dox, in which a methylene group bridges the oxygen and nitrogen of the daunosamine, 
forming an oxazolidine (Figure 1, methylene highlighted in red).6 The addition of another 
equivalent of formaldehyde leads to formation of a Doxaz dimer, doxoform (DoxF), which has 
been shown to act as Doxaz prodrug.6 Despite differing from Dox by just a single atom, Doxaz  
 
Figure 1. Structures of doxorubicin (Dox), doxazolidine (Doxaz), and doxoform 
(DoxF). Highlighted in red on Doxaz is the single methylene difference. 
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exhibits a superior therapeutic profile than that of Dox. Doxaz inhibits cancer cell growth with 
100-10,000 times the efficacy of Dox, including notable activity against Dox resistant cell lines.6 
While Doxaz displays this greater antitumor potency, treatment of rat cardiomyocytes does not 
result in increased toxicity relative to Dox.6 
There is a fundamental explanation of the differences between Doxaz and Dox. The 
mechanism by which Doxaz triggers cell death is inherently different than that of Dox. Doxaz is 
topoisomerase II independent; instead, it forms a virtual cross-link across 5’-GC-3’ DNA base 
pairs (Figure 2).6-7 Because of this, Doxaz is better considered as a new therapeutic rather than an 
improved Dox. 
With a distinct mechanism and 
favorable therapeutic profile, Doxaz is 
an attractive new drug; however, a 
conventional approach to Doxaz 
treatment is not feasible. In aqueous 
solution, Doxaz is rapidly hydrolyzed 
to Dox with a half-life of three 
minutes.6 This problem is alleviated using a prodrug strategy, in which an inactive form of a 
therapeutic is activated in vivo to release the active form at a specific location. High potency and 
a short half-life make Doxaz an ideal candidate for prodrug delivery. This approach also allows 
for greater tumor specificity with proper prodrug design. 
Employing the prodrug strategy, the Koch group recently described a pentyl carbamate 
prodrug of Doxaz, pentyl-PABC-Doxaz (PPD, Figure 3), designed for enzymatic activation by 
carboxylesterase 2 (CES2).8 The drug produced favorable results in animal trials, exhibiting  
Figure 2. Virtual cross-link of DNA by 
Doxaz. Figure courtesy of Dr. Ben Barthel.  
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Figure 3. Structures of Doxaz prodrugs Ac-GaFK-PABC-Doxaz (PAD, left), 
pentyl-PABC-Doxaz (PPD, right). Highlighted in red are the enzymatic specific 
tags, and in blue are the self-eliminating spacers. 
 
Scheme 1. Proposed PAD activation pathway via the protease plasmin. 
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substantial tumor growth inhibition in mice; furthermore, prodrug treatment displayed 
significantly lower signs of cardiotoxicity in the test mice at higher doses relative to Dox.9 
These positive results buoy a generic model for Doxaz prodrugs, in which a tag for 
targeted activation is attached to Doxaz using a self-eliminating spacer. This provides versatility 
in treating different tumor types. Following this model, another enzyme-activated prodrug has 
been developed for targeted activation by the protease plasmin. Originally modeled after aFK-
Dox designed by de Groot et al.,10 Ac-GaFK-PABC-Doxaz, or Protease-Activated Doxazolidine 
(PAD), consists of an N-acetyl glycine-D-alanine-L-phenylalanine-L-lysine (Ac-GaFK) 
tetrapeptide tag to a p-aminobenzyloxycarbonyl (PABC) spacer coupled to Doxaz (Figure 3). 
The protease plasmin is proposed to hydrolyze the bond between the peptide and spacer in the 
first step of activation (Scheme 1). Following a spontaneous 1,6 elimination of the spacer to 
release the iminoquinone methide and a subsequent spontaneous decarboxylation, Doxaz is 
liberated at the tumor site. 
Plasmin is an ideal target enzyme for site-specific prodrug activation, as it is a hallmark 
of invasive cancers.11 Involved in the breakdown of extracellular matrix proteins, plasmin is a 
crucial component of tumor proliferation and metastasis.11 First secreted as the zymogen 
plasminogen, plasmin activation occurs at the cell surface via serine protease urokinase-type 
plasminogen activator (uPA).11 The membrane tethered uPA receptor (uPAR) binds uPA to form 
an active complex which cleaves plasminogen to produce active plasmin (Figure 4).11 The 
presence of inhibitors in the bloodstream limit plasmin proteolytic activity to tumor sites;11 thus, 
unwanted prodrug activation in circulation is unlikely. 
With plasmin established as a therapeutic target, PAD research in the Koch laboratory 
has been focused on multiple facets of drug development, the first of which being a scalable  
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Figure 4. Urokinase-type plasminogen activator system. Figure courtesy of Dr. 
Ben Barthel. 
synthesis. The current synthesis of PAD is hampered by a problematic deprotection of the final 
product, resulting in variable quality and loss of material. A new pathway is necessary for 
production of enough material for future animal studies. The first section of this thesis describes 
steps toward a key intermediate in a new PAD synthetic pathway. 
The second prominent area of PAD research is one of preliminary evaluation. Enzyme 
kinetics and cell growth inhibition experiments provide proof of concept and a forecast of 
potential therapeutic success. The plasmin-PAD enzyme-substrate relationship was examined 
through timecourse and Michaelis-Menten kinetics. Drug activation and efficacy was further 
evaluated against multiple cell lines through various half maximal inhibitory concentration (IC50) 
assays, employing exogenous plasmin and a panel of protease inhibitors. 
The final aspect of PAD research presented here is an investigation of the role of 
endogenous plasmin activation in cells. Using short hairpin RNA (shRNA) mediated RNA 
interference (RNAi), both uPA and uPAR were targeted for knockdown in the cancer cell lines 
N-HepG2 (liver), which has shown 5-fold reduction of PAD response in the presence of 
aprotinin (Koch lab unpublished data), and DU-145 (prostate), which express moderate to high 
levels of both uPA and uPAR mRNA.12-13 Knockdown cell lines were then to be assayed for 
PAD activation and efficacy through IC50 experiments. 
  10 
These three elements of PAD research contribute to the overarching objective in 
doxazolidine research. Successful implementation of the prodrug strategy may lead to a new 
clinical therapeutic for a variety of invasive cancers. 
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Results and Discussion 
1. Steps Towards the Synthesis of PAD 
In the current synthesis of PAD, a late-stage deprotection of the lysine residue in the 
peptide results in complicated purification and poor yield. The anthracycline moiety is prone to 
side reactions under many deprotection conditions, resulting in a convoluted mixture of products. 
An ideal PAD synthesis would allow for deprotection of the peptide prior to coupling with 
Doxaz. Described here are steps towards such a synthesis. 
From Scheme 2, diazotization followed by displacement with azide converted 
commercially available p-aminobenzyl alcohol, 1, to azide 2 in 83% yield. Carbonate 3 was 
isolated in 66% yield upon reaction of 2 with 4-nitrophenyl chloroformate. Degradation of 3 on 
silica was observed, likely resulting in the majority of observed product loss. 
Conversion of Dox•HCl to Doxaz via reaction of the free base with formaldehyde was 
almost quantitative (98%). 1H NMR analysis suggested that upon concentration of the reaction 
mixture, excess formaldehyde present caused the formation of DoxF resulting in a 2:1 mixture of 
Doxaz/DoxF. Reaction of the mixture with carbonate 3 produced the desired azide 5 in 38% 
yield isolated by flash chromatography. The presence of both Doxaz and DoxF did not seem to 
hinder the reaction.  We proposed that trace water in the reaction solvent preferentially 
hydrolyzed the DoxF dimer to 2 equiv. of Doxaz without significantly hydrolyzing Doxaz. 
Reaction progress determined by reverse-phase HPLC suggested near complete consumption of 
starting material to produce a single major product. In light of this evidence, low isolation yield 
is most likely attributed to anthracycline degradation on silica during flash chromatography. 
Strong streaking was observed, leaving the silica with a pink appearance regardless of solvent 
system polarity. Isolation by HPLC may prove a better alternative. 
  14 
 
Scheme 2. PAD synthesis pathway. (i) NaNO2, HCl, 0 °C; (ii) NaN3, 0 °C; (iii) 4-nitrophenyl-
chloroformate, pyridine, rt; iv) NaHCO3 4 °C;  (v) paraformaldehyde, rt; (vi) SPPS; (vii) 40 °C. 
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Peptide 4 was synthesized using solid phase peptide synthesis from Fmoc-Lys(Z)-OH – 
where Z corresponds to a benzyloxycarbonyl side-chain protecting group – loaded on a 2-
chlorotrityl resin. The tetrapeptide was recovered in 45% yield following cleavage from resin 
and isolation. Poor peptide solubility in organic solvents contributed to low yield. 
With key intermediate 5 produced in a 20% overall yield across six steps in a 
straightforward, scalable manner, complete synthesis of PAD via this pathway is a foreseeable 
goal. Amidative coupling of azide 5 to the C-terminus of deprotected 4 should afford PAD. The 
early deprotection of 4, in addition to optimization of preceding steps to boost the overall yield 
of intermediate 5, should provide a pathway capable of producing ample material for biological 
studies. 
 
2. Enzymatic and Cellular Studies with PAD 
2.1 Enzyme Kinetics 
Turning to preliminary evaluation of PAD, timecourse and Michaelis-Menten kinetics 
experiments show that Plasmin and PAD exhibit standard enzyme-substrate behavior (Figure 5).  
 
Figure 5. Plasmin-catalyzed PAD activation kinetics at 37 ºC. Timecourse kinetics (left) 
Michaelis-Menten kinetics (right). 
R2 = 0.999 
Vmax = 3.8 ± 0.4 µM/min Dox 
Km = 170 ± 40 µM 
R2 = 0.999 
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Figure 6. Representative HPLC chromatogram of enzymatic activation of PAD, with peaks 
corresponding to Dox and PAD labeled accordingly. Monitored at 480 nm. 
The timecourse was evaluated as the production of Dox over time; because of the rapid 
hydrolysis of Doxaz to Dox, a direct measurement of Doxaz is difficult by HPLC. In the absence 
of plasmin, PAD is stable and no Doxaz is released; therefore, any Dox observed must be a result 
of enzymatic cleavage of the prodrug. 
The presence of only two peaks in the 480 nm HPLC chromatogram (Figure 6) allows for 
simple determination of percent conversion. The percentage of the Dox peak (~6 min) relative to 
the prodrug peak (~9 min) is directly indicative of percent conversion, since all unstable 
intermediates, including those formed between enzyme hydrolysis and release of Doxaz, are too 
short-lived to see by HPLC. In this experiment, plasmin catalyzed conversion of PAD to Doxaz 
– and subsequent hydrolysis to Dox – is shown to approach completion (88%) within 2.5 h, 
representing fast and efficient enzymatic turnover.  
Using the same analysis, plasmin PAD activation is shown to fit the standard Michaelis-
Menten model with observed Vmax and Km values of 3.8 ± 0.4 µM Dox min-1 and 170 ± 40 µM 
PAD, respectively; however, such behavior was not initially apparent. Previous Michaelis-
Menten kinetics experiments employing high concentrations of acidic buffer in the drug 
PAD 
Dox 
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formulation resulted in an observed inhibitory effect at high concentrations. Relative plasmin 
activity notably decreased at PAD concentrations above 100 µM, rather than the leveling off 
expected when approaching Vmax. Experiments employing formulated PAD containing saline and 
10% PEG-400 did not reproduce the observed inhibition, and instead displayed the Michaelis-
Menten described above. Because formulated drug will be used in more advanced studies, such 
as animal experiments, the obtained kinetics are most relevant to current research. 
 
2.2 Cancer Cell Growth Inhibition Studies  
With this evidence for enzyme-catalyzed activation, PAD-induced cancer cell growth 
inhibition can be explored. PAD alone was shown to be quite effective in inhibiting growth in 
BxPC3 (pancreatic), MiaPaCa2 (pancreatic), and SHP77 (small-cell lung) cancer cell lines, with 
IC50 values in the micromolar and nanomolar levels (Table 1). PAD efficacy increased by more 
than an order of magnitude in the presence of exogenous plasmin, confirming the release of a 
more potent cytotoxic agent, Doxaz. This result serves as precedent for PAD activation to Doxaz 
by plasmin in complex systems. 
A more puzzling discovery made by Dr. Barthel of the Koch lab, is PAD efficacy appears 
to be unaffected by the presence of a known plasmin inhibitor aprotinin. This result suggests 
PAD activation may occur by alternative avenues, prompting a closer examination of PAD 
activation in cell culture.  
Treatment 
logIC50 
BxPC3 MiaPaCa2 SHP77 
PAD -6.39 ± 0.04 -6.62 ± 0.03 -5.80 ± 0.03 
PAD + Plasmin -7.8 ± 0.3 -7.96 ± 0.07 -7.53 ± 0.05 
PAD + Aprotinina -6.3 ± 0.1 -6.56 ± 0.03 — 
Table 1. IC50 values expressed as the log of the half maximal inhibitory 
concentration in mol L-1. aUnpublished data from the Koch lab. 
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In an attempt to elucidate the alternative pathway(s) of PAD activation, a panel of 
protease inhibitors was utilized in IC50 assays to determine the protease class(es) responsible for 
activation (Figure 7). Included in the panel were protease inhibitors bestatin (amino peptidases), 
phosphoramidon (metallo endopeptidases), E-64 (cysteine proteases), leupeptin (serine and 
cysteine proteases), and a complete protease inhibitor cocktail. The conclusion drawn from the 
previous aprotinin experiments was confirmed. Complete protease inhibition resulted in a 
decrease in efficacy relative to PAD alone.  
Interestingly, leupeptin, and to some extent E-64, returned as positive hits in the panel, as 
both decreased PAD efficacy. It appears PAD 
activation in cell culture occurs via a 
combination of serene and cysteine proteases. 
An intriguing prospect of these results is the 
determination of other proteases as activation 
candidates. One enzyme of note is the cysteine 
protease cathepsin B – shown to cleave peptides 
after Phe-Lys sequences.1 Cathepsin B is also 
associated with invasive tumors;2 therefore, 
cysteine protease catalyzed prodrug cleavage 
may increase the scope of cancers treatable with 
PAD. 
 
3. shRNA knockdown of uPA and uPAR in N-HepG2 and DU-145  
Although the protease inhibition panel provided insight as to a potential alternative class 
of proteases capable of PAD activation, the study provides little as to the direct role in PAD 
Figure 7. PAD IC50 values for MiaPaCa2 
cell growth inhibition in the presence of a 
panel of protease inhibitors. 
***Significant difference from no 
inhibitor with a p-value < 0.001. 
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efficacy assumed by plasmin and the uPA system. In order to address this, uPA and uPAR were 
targeted for knockdown in both N-HepG2 (liver) and DU-145 (prostate) cancer cell lines. 
Knockdown was achieved using shRNA-mediated RNAi. To produce stable, permanent 
knockdown lines, shRNA constructs were introduced retrovirally. Constructs were selected from 
the Sigma MISSION database of shRNA sequences and were prepared by the Functional 
Genomics facility at the University of Colorado – Boulder. Two constructs per protein product 
were employed: shPLAU.88 and shPLAU.89 for uPA; shPLAUR.35 and shPLAUR.37 for 
uPAR. The targets of the constructs are mapped in Figure 8. Puromycin resistance was included 
in the retroviral package for selection of infected cells. 
Cells were readily infected and puromycin-resistant clones were selected and grown up.  
Future studies will examine the expression of targeted genes in the clones and will assess their 
resistance to PAD treatment by IC50 assays. 
 
  
Figure 8. Target sites on uPA (top) and uPAR (bottom) mRNA of shRNA 
constructs. Green arrows represent exons. Blue arrows represent translated 
regions. Figure courtesy of Dr. Ben Barthel.  
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Conclusion 
This research offers an optimistic outlook on PAD treatment feasibility. Key intermediate 
5 in a new synthetic strategy towards PAD was produced in 20% overall yield over 6 steps. 
Although this figure is not ideal, the simplicity of the antecedent reactions suggests optimization 
could dramatically increase overall yield. At the forefront of optimization is an effort towards 
discerning more appropriate purification techniques. Despite the purification issues, an 
encouraging element of the synthetic pathway is the scalable potential of each reaction. This 
synthesis has the capacity to provide ample material for biological assays. 
This research also contributed proof of concept for targeted PAD activation by plasmin. 
In both timecourse and Michaelis-Menten kinetic assays, plasmin was shown to exhibit standard 
enzyme substrate behavior with rapid and efficient conversion when using PAD as a substrate. 
This activation was further observed in cancer cells. PAD treatment alone exhibited impressive 
cell growth inhibition with IC50 values at the nanomolar level, and the presence of exogenous 
plasmin led to an increase in efficacy of more than an order of magnitude. Though a major 
player, plasmin was found to be one of multiple enzymes involved in PAD activation in cell 
culture. 
Protease inhibitor studies revealed that PAD activation is not exclusively plasmin 
specific. Instead, a combination of serine and cysteine proteases is responsible for prodrug 
activation. Further research may shed light on the specific enzymes contributing to PAD 
efficacy. The cysteine protease cathepsin B is of particular interest due to its known association 
with invasive tumors. 
Due to a degree of non-specificity in protease inhibitors, the role of plasmin was probed 
at a more specific level. N-HepG2 and DU-145 cell lines were successfully infected with shRNA 
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constructs targeting mRNA of uPA and uPAR and cloned. Current experiments are in place to 
assay uPA and uPAR expression in knockdown clones and their resistance to PAD treatment.  
Resistant knockdown lines will provide a platform for future cell culture and animal studies 
concerning plasmin-mediated activation. 
Considering the benefits of a replacement to Dox treatment, these findings are certainly 
encouraging. Should future animal studies reflect these promising results, PAD may prove to be 
a clinically valuable chemotherapeutic. 
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Experimental 
General Remarks 
Synthesis reagents were purchased from Sigma-Aldrich (St. Louis, MO) and EMD 
Millipore (Billerica, MA). Deuterated solvents were obtained from Cambridge Isotope 
Laboratories (Andover, MA). NMR spectra were obtained on a Bruker Avance-III 300 NMR 
Spectrometer. IR spectra were obtained using a Thermo Nicolet Avatar 360 FT-IR Spectrometer. 
Plasmin, protease inhibitors, and primary antibodies were obtained from Sigma-Aldrich (St. 
Louis, MO), Roche (Basel, Switzerland), and Santa Cruz Biotechnology (Santa Cruz, CA), 
respectively. Optical density measurements were made using a Hewlett-Packard 8452A Diode 
Array Spectrophotometer or a BioTek Instruments PowerWave X microplate reader. Reverse-
phase HPLC analysis was performed using a Hewlett-Packard 1050/1100 instrument with an 
Agilent 4.6 x 150 mm reverse-phase column with 5 µm, C18 packing. 
Abbreviations 
NMR nuclear magnetic resonance, TLC thin layer chromatography, DCM 
dichloromethane, Dox doxorubicin, Doxaz doxazolidine, DoxF doxoform, PAD Protease-
Activated Doxazolidine, DMSO dimethyl sulfoxide, HPLC high performance liquid 
chromatography, DIPEA N,N-diisopropylethyl amine, MeOH methanol, EtOH ethanol, DBU 
1,8-diazabicyclo[5.4.0]undec-7-ene, Fmoc fluorenylmethyloxycarbonyl, KOH potassium 
hydroxide, HBTU O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate, 
HOBt 1-hydroxy-1H-benzotriazole, TFA trifluoroacetic acid, PBS phosphate buffer saline, IC50 
half maximal inhibitory concentration, Koch U µM Dox min-1, shRNA short hairpin RNA, uPA 
urokinase-type plasminogen activator, uPAR urokinase-type plasminogen activator receptor, 
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DMEM Dulbecco’s Modified Eagle Medium, RPMI Roswell Park Memorial Institute medium, 
FBS fetal bovine serum, Pen/Strep penicillin-streptomycin. 
 
1. Experimental for Steps Towards the Synthesis of PAD 
4-Azidobenzyl alcohol, 2 
As previously reported,1 a 1.8 M solution of sodium nitrite in water (8.5 mL) was added 
in portions by pipet over a period of 30 min to 4-aminobenzyl alcohol (10 mmol) stirred in 5 M 
HCl (20 mL) at 0 ºC. Sodium azide (40 mmol) was then added in small portions over an 
additional 30 min at 0 ºC, allowing for N2 effervescence. The reaction mixture was stirred for 
another 1 h at 0 ºC. The reaction mixture was then poured into ice water (25 mL) and basified to 
pH ~8 using sodium bicarbonate. Following extraction into ethyl acetate (3x25 mL washes), the 
combined organic layers were dried over magnesium sulfate, filtered, and concentrated via rotary 
evaporation at ambient temperature. The yellow oil obtained was then triturated with light 
petroleum to afford the desired azide as cream, needle crystals. 1H NMR (300 MHz, CDCl3) δ 
7.37 (2H, m, Ar), 7.03 (2H, m, Ar), 4.69 (2H, d, J = 5 Hz, CH2), 1.62 ppm (1H, t, J = 5 Hz, OH). 
13C NMR (75 MHz, CDCl3) δ 139.61, 137.79, 128.75, 119.35, 64.97 ppm. IR 2110 cm-1 (azide). 
4-Azidobenzyl-4’-nitrophenyl carbonate, 3 
Following the transformation reported by Griffin et al.,1 a solution of 4-azidobenzyl 
alcohol (12 mmol) in DCM (100 mL) was added dropwise over 30 min to a stirred solution of 4-
nitrophenyl chloroformate (12.5 mmol) and pyridine (24 mmol) in DCM (70 mL) at 0-4 ºC. The 
reaction mixture was stirred for an additional 72 h at room temperature until all starting materials 
were consumed as determined by silica gel TLC eluting with 50:50 hexanes/ethyl acetate. The 
DCM was removed via rotary evaporation. The resulting solid was dissolved in ethyl acetate (10 
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mL), washed with water (3x50 mL), dried over magnesium sulfate, and isolated via rotary 
evaporation. The resulting solid was then isolated via flash chromatography. 1H NMR (300 
MHz, CDCl3) δ 8.29 (2H, m, Ar-3’,5’), 7.45 (2H, m, Ar-2,5), 7.38 (2H, m, Ar-2’,5’), 7.08 (2H, 
m, Ar-3,5), 5.27 ppm (2H, s, CH2). 13C NMR (75 MHz, CDCl3) δ 155.66, 152.63, 141.22, 
130.70, 125.53, 121.96, 119.74, 70.57 ppm. 
Doxazolidine 
An expired clinical sample of Dox•HCl (34 µmol) obtained as a lyophilized pellet 
containing 100 mg lactose monohydrate was dissolved in 15 mL of saturated sodium bicarbonate 
(pH ~8) and extracted into chloroform (20 mL) eight times. All chloroform fractions were 
combined, dried over sodium sulfate, filtered, and rotary-evaporated to dryness. The Dox free 
base was dried under high vacuum (10-2 Torr). The free base was then dissolved in deuterio-
DMSO (15 mL) and 1.5 equiv. of prilled-paraformaldehyde was added. The mixture was stirred 
at room temperature under an argon atmosphere and monitored by 1H NMR for completion. 
Upon completion, the DMSO was removed using high vacuum (10-2 Torr) rotary evaporation, 
and reaction yield was determined by anthracycline absorbance at 480 nm assuming an 
extinction coefficient of 11,500 M-1 cm-1. 1H NMR suggested the formation of a mixture of 
Doxaz and DoxF based on previous peak assignments.2 The crude mixture was carried forward 
without further purification or characterization. 
4’’-Azidobenzyloxy carbonyl Doxaz, 5 
Carbonate 3 (1.0 equiv.) was added to doxazolidine in 1.0 mL of DMSO. The reaction 
was monitored by HPLC until completion (~2 days). After diluting of the reaction mixture with 
25 mL of aqueous saturated sodium bicarbonate, crude product was obtained by extraction with 
chloroform (8 x 10 mL). The chloroform extracts were combined and dried over sodium sulfate. 
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The extraction mixture was then concentrated via rotary evaporation. Isolated crude product was 
then subject to flash chromatography for purification. Yield and purity were determined via 
optical density and HPLC, respectively. 1H NMR (300 MHz, CDCl3) δ 13.96 (1H, s, Ar-OH), 
13.25 (1H, s, Ar-OH), 8.04 (1H, m, 1), 7.80 (1H, m, 2), 7.41 (1H, m, 3), 7.36 (2H, m, 2”), 7.02 
(2H, m, 3”), 5.47 (1H, t, J = 5 Hz, 1’), 5.31 (1H, s, 7), 5.13 (2H, s, Bz), 5.02 (2H, m, O-CH2-N), 
4.76 (2H, d, J = 5 Hz, 14), 4.73 (1H, s, 9-OH), 4.10 (3H, s, O-Me), 4.10 (3H, m, 3’,4’,5’), 3.27 
(1H, m, 10), 3.02 (1H, m, 10) 3.02 (1H, t, J = 5 Hz, 14-OH), 2.44 (1H, m, 8), 2.29 (1H, m, 2’), 
2.16 (1H, m, 8), 1.78 (1H, m, 2’), 1.36 ppm (3H, d, J = 6 Hz, 5’-Me). 
N-Acetyl-GaFK(Z)-OH, 4 
Fmoc-Lys(Z)-OH (1 mmol) was added to DIPEA (4 mmol) in 2.5 mL dry DCM. Dry 
DMF was added dropwise to facilitate dissolution of the amino acid. To this solution, 0.25 g 2-
chlorotrityl chloride resin was added. The resulting mixture was stirred for 120 min, filtered, 
stirred with 95/5 MeOH/DIPEA for 30 min, filtered, and subsequently washed three times with 
DCM/MeOH/DIPEA (17:2:1), followed by ten iterations of alternating DCM and MeOH 
washes. The loaded resin was then dried in vacuo over KOH. Loading capacity was determined 
using DBU Fmoc deprotection in the absence of piperidine, monitoring the optical density of 
dibenzofulvene at 294 and 304 nm. 
Once dry, an Applied Biosystems 433A peptide synthesizer was used for automated 
synthesis of the Ac-GaFK(Z)-OH tetrapeptide employing DBU and piperidine Fmoc 
deprotection and HBTU/HOBt activation. 
Dried peptide on resin was swollen with DCM and filtered. TFA (1%) in 1.5 mL of DCM 
was added to the resin and stirred for 2 min. The solution was filtered through a sintered glass 
funnel using positive argon pressure into a flask containing 0.3 mL of 10% pyridine in MeOH. 
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This process was repeated 10 times, after which the resin was washed with ten iterations of 
alternating DCM and MeOH washes. The volume of the filtrate was reduced to 5% via rotary 
evaporation. Ether was added to the flask to precipitate the peptide. The ether solution was then 
poured off and the peptide precipitate was dried under reduced pressure. 1H NMR (300 MHz, d6-
DMSO) δ 12.32 (1H, s, K-OH) 8.33 (1H, m, Kα-NH), 8.14 (1H, t, J = 6 Hz, G-NH), 7.99 (1H, d, 
J = 7 Hz, a-NH), 7.91 (1H, d, J = 7 Hz, F-NH) 7.33 (5H, m, Z-Ar), 7.23 (5H, m, F-Ar), 7.18 (1H, 
m, Kε-NH), 4.99 (2H, s, Z-CH2), 4.50 (1H, m, K-α), 4.27 (1H, quin, J = 7 Hz, a-α), 4.06 (1H, q, J 
= 7 Hz, F-α), 3.67 (2H, d, J = 6 Hz, G-α), 3.09 (1H, m, K-β), 2.97 (2H, m, F-CH2), 2.74 (1H, m, 
K-β), 1.83 (3H, s, Ac-CH3), 1.72-1.35 (6H, m, K-γ,δ,ε), 0.91 ppm (3H, d, J = 7 Hz, a-CH3). 
 
2. Experimental for Enzymatic and Cellular Studies with PAD 
2.1 Enzyme Kinetics 
Plasmin timecourse 
A 350 µL solution of 50 µM PAD in 5% DMSO, 95% PBS was incubated with plasmin 
(3.2 Koch U mL-1) at 37 ºC. A 50 µL aliquot was removed at each time point (2 min, 5 min, 10 
min, 30 min, 1 h, and 2 h), quenched with an equal volume of EtOH, and stored at -20 ºC. The 
aliquots were then analyzed using reverse-phase HPLC eluting with a gradient of 20 mM sodium 
phosphate pH 4.0 buffer containing 0.02% sodium azide with acetonitrile starting at 80% buffer, 
to 60% buffer at 5 min, to 30% buffer at 10 min, to 20% buffer at 13 min, isocratic to 15 min, to 
40% buffer at 16 min, and to 80% buffer at 17 min, while detecting at 480 nm. 
Michaelis-Menten kinetics 
Aliquots of formulated PAD were diluted with PBS to provide the desired prodrug 
concentrations (10 µM, 25 µM, 50 µM, 75 µM, 100 µM, 200 µM, 300 µM, and 400 µM). Upon 
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addition of plasmin for a final concentration of 3.8 Koch U mL-1, each aliquot was incubated at 
37 ºC for 4 min, then quenched with an equal volume of EtOH and stored at -20 ºC. The 
mixtures were then analyzed by HPLC eluting with a gradient of 10 mM phosphate pH 4.0 
buffer containing 0.02% sodium azide with acetonitrile starting at 80% buffer, to 60% buffer at 5 
min, to 50% buffer at 8 min, isocratic to 9 min, and to 80% buffer at 11 min, while detecting at 
480 nm. 
 
2.2 Cancer Cell Growth Inhibition 
General IC50 assay 
Cells were plated in 96 well plates at ~1000 cells per well and incubated overnight. 
Growth media (RPMI or DMEM with 10% FBS and 1% Pen/Strep) was replaced with serum 
free media containing various PAD concentrations for a 24 h treatment period. Treatment media 
was then replaced with fresh, complete media, and the cells were left to grow for 5 days or to 
~80% confluence. Cells were then fixed with 5% formalin in PBS and quantified by uptake of 
crystal violet. Solubilized in 4:1:1 EtOH/MeOH/water, crystal violet optical density was 
measured at 588 nm. Each drug condition was repeated six times, and each experiment was 
duplicated. 
In specified experiments, exogenous enzyme was administered in the treatment media at 
a concentration of 3.8 Koch U mL-1. Protease inhibition experiments were performed by addition 
of inhibitors to treatment media in IC50 assays. The inhibitors and their concentrations used were 
as follows: a total protease inhibitor cocktail (Complete Mini, Roche) made to 1x according to 
the manufacturer’s instructions, 28 µM E-64 (cysteine proteases), 10 µM leupeptin (serine and 
cysteine proteases), 600 µM phosphoramidon (metallo endopeptidases), and 130 µM bestatin 
(amino peptidases). 
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3. Experimental for shRNA knockdown of uPA and uPAR in N-HepG2 and DU-145  
Retroviral infection 
Retroviral supernatants for each of the 6 shRNA constructs were ordered from Sigma’s 
MISSION shRNA program and viral supernatants from the Functional Genomics Facility at the 
University of Colorado – Boulder. Cells were grown to ~50% confluence in 6-well plates then 
incubated with a retroviral cocktail of two-thirds DMEM, one-third retroviral supernatant 
containing 4 µg mL-1 polybrene. After 24 h the media was removed and the cells were incubated 
for a further 48 h in fresh DMEM. To select infected cells, puromycin was administered with an 
in-well concentration of 5 µg mL-1 for an incubation period of 24 h. Resistant cells were split and 
plated on 10 cm plates at 100 cells per plate for cloning. Clone colonies were then harvested for 
knockdown screening. 
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